




BMJ Open Prevalence and changes of low-value care at acute care hospitals: a multicentre observational study in Japan

Atsushi Miyawaki ^{1,2}, Ryo Ikesu,³ Yasuharu Tokuda ^{4,5}, Rei Goto,⁶ Yasuki Kobayashi,² Kazuaki Sano,² Yusuke Tsugawa ^{1,7}

To cite: Miyawaki A, Ikesu R, Tokuda Y, *et al.* Prevalence and changes of low-value care at acute care hospitals: a multicentre observational study in Japan. *BMJ Open* 2022;**12**:e063171. doi:10.1136/bmjopen-2022-063171

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-063171>).

Received 24 March 2022

Accepted 15 August 2022

ABSTRACT

Objectives We aimed to examine the use and factors associated with the provision of low-value care in Japan.

Design A multicentre observational study.

Setting Routinely collected claims data that include all inpatient and outpatient visits in 242 large acute care hospitals (accounting for approximately 11% of all acute hospitalisations in Japan).

Participants 345 564 patients (median age (IQR): 62 (40–75) years; 182 938 (52.9%) women) seeking care at least once in the hospitals in the fiscal year 2019.

Primary and secondary outcome measures We identified 33 low-value services, as defined by clinical evidence, and developed two versions of claims-based measures of low-value services with different sensitivity and specificity (broader and narrower definitions). We examined the number of low-value services, the proportion of patients receiving these services and the proportion of total healthcare spending incurred by these services in 2019. We also evaluated the 2015–2019 trends in the number of low-value services.

Results Services identified by broader low-value care definition occurred in 7.5% of patients and accounted for 0.5% of overall annual healthcare spending. Services identified by narrower low-value care definition occurred in 4.9% of patients and constituted 0.2% of overall annual healthcare spending. Overall, there was no clear trend in the prevalence of low-value services between 2015 and 2019. When focusing on each of the 17 services accounting for more than 99% of all low-value services identified (narrower definition), 6 showed decreasing trends from 2015 to 2019, while 4 showed increasing trends. Hospital size and patients' age, sex and comorbidities were associated with the probability of receiving low-value service.

Conclusions A substantial number of patients received low-value care in Japan. Several low-value services with high frequency, especially with increasing trends, require further investigation and policy interventions for better resource allocation.

INTRODUCTION

Low-value care or healthcare that provides no net clinical benefit to patients¹ remains a challenge that plagues healthcare systems worldwide.^{2–3} Low-value care contributes to increased health expenditures, is potentially

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This is the first study investigating the frequency, healthcare costs and trends of low-value care in Japan.
- ⇒ We identified and examined 33 low-value services based on a rigorous literature search.
- ⇒ We used routinely collected claims data across as many as 242 acute care hospitals (accounting for approximately 11% of all discharges in Japan).
- ⇒ We did not consider other possible inappropriate care; further research investigating more evidence-based low-value care will be needed.
- ⇒ We did not examine medical facilities other than acute care hospitals, such as outpatient clinics, non-acute care hospitals and nursing homes.

associated with iatrogenic harms associated with overdiagnosis and overtreatment and often interferes with the delivery of quality care. Since the American Board of Internal Medicine launched the 'Choosing Wisely' initiative in 2012 to identify low-value care commonly used in medical practice,⁴ similar clinical-led initiatives have been introduced in more than 20 countries.⁵ To minimise low-value care, it is imperative to identify and directly measure it and, more importantly, to understand the factors associated with providing it.

Despite increased awareness of the importance of identifying low-value care globally, most studies have focused on the magnitude of these practices in North America.^{6–10} Outside of North America,^{11–13} studies have been conducted in Australia^{11–13} and Austria,¹⁴ but these studies focused only on inpatient services provided in hospitals. There is another study from the Netherlands,¹⁵ but this study evaluated only three diagnostic services. The extent to which low-value care is used in inpatient and outpatient settings remains largely unknown in other countries, including Japan. In Japan, the provision of healthcare services has been strictly



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Atsushi Miyawaki;
amiyawaki-ty@umin.ac.jp

controlled by the government (eg, the scope of health-care services reimbursed by health insurance, as well as their unit price, are determined by the fee schedule developed centrally by the government) under the social insurance system,¹⁶ and, therefore, it is possible that the utilisation of low-value care may be less common in Japan compared with the USA. This category of social insurance schemes in healthcare, as Japan is classified, includes several states such as Germany, France, South Korea and Taiwan.¹⁶ As there is limited information regarding overuse on a global scale, measuring low-value care in healthcare settings like Japan can extend our knowledge on the factors associated with use of low-value care and inform recent international collaborations to address wasteful clinical care.^{5 17}

In this context, we aimed to examine low-value care in inpatient and outpatient settings of Japanese acute care hospitals by using large-scale hospital claims data. We first identified a measurable list of low-value care based on previous studies and recommendations specified by a group of specialists according to independent literature review. We then measured the amount of low-value care and its associated healthcare spending according to algorithms to identify low-value care that could apply to hospital claims data with reasonable accuracy. Finally, we evaluated factors associated with low-value care use.

METHODS

Setting

We first briefly describe the health insurance and payment system in Japan. Japan has achieved universal health coverage in 1961.¹⁸ Japanese residents are legally obligated to purchase one of the health insurance programmes that consist of the employment-based health insurance, residence-based health insurance (for non-elderly self-employed and unemployed people) or age-based health insurance programme (for individuals aged 75 years or older). The scope of benefits covered by these health insurance programmes is standardised among insurers by the government, including inpatient and outpatient care, dental care, physical rehabilitation, home healthcare and prescriptions. Regardless of the healthcare services provided, the coinsurance rate is the same for all insurers (eg, adults younger than 70 years pay 30%) without deductibles, and including a catastrophic coverage provision.¹⁹ The payment method by which insurers pay acute care hospitals differs between outpatient and inpatient care. Outpatient care is reimbursed under the fee-for-service (FFS) system. Among the costs of inpatient care, hospital fees (bed charges) are paid by the insurers under the per-diem reimbursement (a fixed amount per inpatient day, according to diagnosis categories, under a mechanism known as Diagnosis Procedure Combination), although the costs of expensive surgeries and therapeutic or diagnostic procedures are exempted and paid through the FFS system.

Data

We used a de-identified hospital claims database from Japanese acute care hospitals that consented to the data utilisation, built by Medical Data Vision Co (Tokyo, Japan).²⁰ This available claims database consists of inpatient, outpatient, emergency care and physician prescription claims, covering all the physician and hospital fees and the healthcare spending of drugs prescribed or used in hospitals. Briefly, the database includes information on patients' demographics, the reimbursement codes for provided healthcare services, diagnoses and routes of hospitalisation.²¹ The database has been appropriately quality-controlled (see online supplemental method 1) and has been used in previous studies.^{21–25} We obtained claims data from 242 continuously observed hospitals that consented to data utilisation from the fiscal year (FY) 2015 through FY2019 (1 April 2015 to 31 March 2020). Our preliminary investigation found that these hospitals had 138 820 discharges in September 2017, which accounted for 11% of all discharges from acute care hospitals in the same month across Japan (n=1.27 million), and the distributions of patients' age, sex and principal diagnosis were comparable to the nationwide estimates, according to the Patient Survey (a triennial survey of patients using nationwide hospitals selected by stratified random sampling) (online supplemental figure 1).²⁶ We analysed a random 5% sample of patients.

Measures of low-value care

First, we conducted a literature review to identify low-value services (online supplemental method 2). In doing this, we listed up to 68 low-value services identified in previous studies conducted in the USA,⁹ in Canada¹⁰ and in Australia,¹¹ as measured by multiple sources, including Choosing Wisely,^{4 27–29} US Preventive Services Task Force 'C' or 'D' recommendations³⁰ and Royal Australasian College of Physicians EVOLVE initiatives.³¹ We also identified 45 low-value services, as defined by robust clinical evidence based on a predetermined literature search method. For this, the members of a selected specialist physicians board (whose specialties are described in online supplemental table 1) proposed candidate low-value services along with clinical evidence, and then several authors double-checked the evidence. After excluding 22 duplicated services (including combining similar services into a single measure) and 58 services that could not be reliably measured using the claims data, we identified a final list of 33 low-value services that could apply to hospital claims data with reasonable accuracy (online supplemental figure 2 and online supplemental table 2). Whether or not the service is 'measurable' in claims data was determined by three authors with sufficient experience in claims data analyses (AM, RI and YTo). For a low-value service to be measurable, we applied the following two criteria:

1. It had to be identifiable in the hospital claims data (healthcare services that are not reimbursed by the Japanese public health insurance system (eg,

preventive medicine services, pregnancy checkups and regular deliveries) are not recorded).

2. It had to be possible to reasonably identify a low-value service with high specificity using the variables in the data (eg, the target area for imaging tests is usually not recorded unless otherwise specified in the Japanese public health insurance claim).

Based on these criteria, we did not include all cancer screening services (eg, prostate-specific antigen testing for men aged ≥ 75 to screen prostate cancer) and some imaging tests (eg, head imaging for syncope and uncomplicated headache and back imaging for low back pain) as a measurable low-value service.

For each of the 33 selected services, we developed an operational definition of a low-value service using the International Classification of Diseases, Tenth Revision (ICD-10) diagnostic codes³² and service reimbursement codes, the timing of care, site of care (outpatient vs inpatient), route of admission and demographic information (online supplemental table 3). We did not distinguish between principal and secondary diagnoses when using ICD-10 diagnosis codes because the flag of principal diagnosis in Japanese claims data is unreliable. It should be noted that there is inherent uncertainty in identifying low-value services using administrative claims data because diagnosis and service reimbursement codes do not necessarily map the actual conditions and diagnostic/therapeutic procedures that patients experience. To account for this uncertainty, following previous studies,^{7 11} we specified two versions of each measure: a broader definition and a narrower definition. First, we created the broader definition to include all low-value care at the risk of misclassifying appropriate care. By adding some criteria to this broader definition, we next created the narrower definition to minimise the misclassification of appropriate care instead of overlooking some low-value care. Although the gold standard for low-value care was not available in this study, if such a gold standard had been available, the narrower definition would have shown lower sensitivity and higher specificity than the broader definition. Operational definitions followed those used in previous studies and were ultimately determined by multiple authors, each of whom was physician accustomed to data analyses using claims data (AM, RI and YTo).

Analysis

We counted low-value care based on episodes of inpatient care, outpatient care or prescription (online supplemental table 2). For example, we counted a series of intravenous treatments administered over several days during hospitalisation as one episode. Focusing on FY2019 data, we identified episodes in which each service was provided (regardless of whether they were low-value or non-low-value) and calculated the number and percentage of the low-value ones. We also calculated the number of low-value care episodes per 1000 patients who saw physicians

at least once and the percentage of patients having at least one of the 33 low-value services in FY2019.³³

Second, we calculated the healthcare spending associated with low-value episodes. To do this, we used official prices under the public health insurance (constant across regions or types of insurance) at the timing of care, FY2019. Although inpatient services are reimbursed by per diem bundled payment in Japan, we calculated healthcare spending based on an FFS payment following the Guideline for Healthcare Spending-Effectiveness Evaluation in the Central Social Insurance Council.³⁴ We included related services for calculating healthcare spending (eg, contrast medium administration for imaging studies or all inpatient services on the day of surgeries) (online supplemental table 3). When multiple low-value services were performed in a single hospitalisation, we added up the costs of those services. Aggregate healthcare spending estimates were multiplied by 20 to approximate healthcare spending for the entire population of patients seeking care from 5% samples. We also calculated the proportion of total healthcare spending for services covered under the public health insurance devoted to low-value episodes. The healthcare spending was reported in Japanese yen (110 JPY=1 US\$ and 140 JPY=1 British pound on average in 2019).

Third, we examined the overall trends in the number of low-value episodes per 1000 patients seeking care from FY2015 to FY2019. This overall analysis evaluated the aggregated number of 31 out of the 33 identified low-value services that were measurable throughout the period (bone mineral testing became measurable in FY2017 and breast MRI in FY2016). We estimated the annual average percentage change in the number of low-value episodes. Furthermore, for each of the 17 services with the most episodes involving low-value care (based on narrower definition) in FY2019, we separately evaluated the trends in the number of low-value episodes per 1000 patients seeking care from FY2015 to FY2019. We analysed the data from the earliest year for bone mineral testing and breast MRI in which the episodes became measurable.

Finally, we regressed the indicator of whether a patient received at least one of the 33 low-value services in FY2019 on the patient's age (continuous), sex and comorbidities (Charlson's comorbidity score at the first visit of FY2019, 0–1, 2–4 and ≥ 5) and the size of the treating hospital (small (number of hospital beds < 200), medium (200–499) and large (≥ 500)) by using logistic regression with Huber-White robust standard errors. We focused on adults aged ≥ 18 because most low-value care measures focused on adults.^{6 9 11} We also repeated the analyses focusing on the probability of receiving an individual low-value service at least once rather than the entire 33 low-value medical services. In doing this, we analysed the two services with most episodes involving low-value care (narrower definition) and the two services accounting for the greatest healthcare spending in FY2019. We considered a p value of less than 0.05 to be statistically significant. All analyses were performed using Stata, V.15.1 (Stata Corp).

Patient involvement

Patients and the public were not directly involved in this study. However, patient perspectives have been heavily involved in various international Choosing Wisely campaigns, the recommendations from which are an important input to this study.

RESULTS

Frequency of low-value care

Among the 345 564 patients who saw physicians at least once in FY2019, we identified 39 657 episodes (115 episodes per 1000 patients) as low value according to the narrower definitions of low-value care (table 1). These accounted for 16.3% of all 243 722 episodes involving any of these services. We also found that 4.9% of patients seeking care (n=16 863) received at least one low-value service identified by the narrower definition. Four services (tricyclic antidepressants prescription for children without other psychological disorders, carotid endarterectomy in asymptomatic patients, nasolacrimal probe in infants and electroconvulsive therapy in children) had no low-value episode in our data. According to the narrower definitions, 17 of 33 services accounted for more than 99% of all low-value episodes. Among them, the majority of spinal injection (86.3%), oral betamimetics prescription (100%), intravenous betamimetics (78.7%) and intravenous sivelestat (100%) were considered to be low value (narrower definitions). Meanwhile, the broader definition identified 75 638 episodes (219 episodes per 1000 patients) as low value, accounting for 31.0% of all episodes involving any of these services. Also, 7.5% of patients seeking care (n=25 815) experienced at least one of these low-value episodes.

Healthcare spending due to low-value care

The total healthcare spending on low-value episodes for these 33 services in FY2019 ranged from JPY 5.7billion (narrower definition) to JPY 12.9billion (broader definition) (table 2). This was 0.23% (narrower) to 0.51% (broader) of the total JPY 2.5trillion healthcare spending of all medical services covered under the public health insurance in FY2019 for the analytic 242 hospitals. According to the narrower definition, spinal injection for low back pain accounted for the most significant total healthcare spending on low-value care (JPY 1.7billion), followed by spinal fusion for lumbar stenosis (JPY 1.0billion), pregabalin prescription for back pain (JPY 0.6billion) and vertebroplasty for osteoporotic vertebral fractures (JPY 0.5billion).

Trends of low-value care

Overall, there was no clear trend in the prevalence of low-value services between 2015 and 2019. The total number of low-value episodes per 1000 patients decreased slightly when using the narrower definition (annual average percentage change, -2.0%; 95% CI, -3.4% to -0.6%; p=0.02) (figure 1 and online supplemental table 4). However, there was no clear trend when using the broad

definition (annual average percentage change, +0.6%; 95% CI, -1.6% to +2.8%; p=0.45).

Among the 17 services accounting for more than 99% of all low-value episodes, 6 showed decreasing trends in the number of low-value episodes per patients seeking care from FY2015 to FY2019 regardless of the low-value care definitions, while 4 showed increasing trends (online supplemental table 5). According to the narrower definition (figure 2), for example, low-value antibiotics prescription decreased annually by 11.5% on average (p=0.001); low-value spinal injection decreased by 7.0% (p=0.001) and low-value oral betamimetics prescription decreased by 6.4% (p=0.03). In contrast, low-value serum triiodothyronine (T3) level testing increased annually by 2.0% on average (p=0.02); low-value pregabalin prescription increased by 17.4% (p=0.01); low-value echocardiogram increased by 4.0% (p=0.002) and low-value hypercoagulability testing increased by 4.9% (p=0.01). These patterns were similar when using the broader definition (online supplemental figure 3).

Factors associated with receiving low-value care

After excluding 42 344 patients aged <18 and 10 945 patients with missing data on comorbidities, we analysed 292 275 patients aged ≥18 years. Online supplemental table 6 shows the crude probability of receiving at least one of the 33 low-value services in FY2019. Our multivariable regression model (table 3) found that older adults had a lower probability of receiving at least one of the 33 low-value services in FY2019, while an additional 10-year increase in patients' age was associated with an adjusted OR (aOR) of 0.90 (95% CI, 0.90 to 0.91; p<0.001). A higher probability of receiving low-value care was associated with being female (female vs male; aOR, 1.37; 95% CI, 1.32 to 1.41; p<0.001) and presenting with more comorbidities (Charlson's score ≥5 vs Charlson's score 0–1; aOR, 2.45; 95% CI, 2.29 to 2.63; p<0.001). Patients treated in larger-size hospitals had a lower probability of receiving low-value care (large vs small; aOR, 0.73; 95% CI, 0.69 to 0.77; p<0.001). When focusing on individual low-value services, patient and hospital characteristics were associated with the probability of receiving low-value care. However, the direction of the association varied by service. For example, a low-value antibiotic prescription was more common among younger adults, while low-value serum T3 testing, spinal injection and spinal fusion were performed more frequently among older adults. Patients treated in larger hospitals had a smaller probability of receiving low-value antibiotics prescriptions but a higher probability of receiving low-value serum T3 testing. Furthermore, the association with Charlson's comorbidity scores was inconsistent across services.

DISCUSSION

Using large-scale hospital claims data, we found that patients seeking care in Japan commonly received low-value care, with 1 in 20 patients (16 863/345 564) using at least one low-value service in FY2019, even when applying narrower definitions of only 33 low-value services. Given

Table 1 Frequency of low-value care (LVC) services in 242 acute care hospitals in the fiscal year 2019

Healthcare services	Narrower definition (high specificity)*			Broader definition (high sensitivity)*		
	No of episodes	No (%) of LVC episodes	No of LVC episodes/1000†	% of patients receiving LVC	No (%) of LVC episodes	No of LVC episodes/1000†
Antibiotics prescription	60344	8159 (13.5)	23.6	1.8	10 164 (16.8)	29.4
Serum T3 level testing	37 620	8061 (21.4)	23.3	0.8	8061 (21.4)	23.3
Pregabalin prescription	60388	7914 (13.1)	22.9	0.4	35 736 (59.2)	103.4
Spinal injection	5659	4883 (86.3)	14.1	0.4	4948 (87.4)	14.3
Oral betamimetics prescription	3425	3425 (100)	9.9	0.2	3425 (100)	9.9
Pulmonary function testing	15920	3287 (20.6)	9.5	0.9	3293 (20.7)	9.3
Echocardiogram	27017	1436 (5.3)	4.2	0.4	1442 (5.3)	4.2
Bone mineral density testing	9157	1021 (11.1)	3.0	0.3	5157 (56.3)	14.9
Hypercoagulability testing	2790	474 (17.0)	1.4	0.04	508 (18.2)	1.5
Intravenous betamimetics	314	247 (78.7)	0.7	0.1	247 (78.7)	0.7
Stress testing	4502	160 (3.6)	0.5	0.04	1760 (39.1)	5.1
Breast MRI	290	96 (33.1)	0.3	0.03	103 (35.5)	0.3
Intravenous sivelestat	66	66 (100)	0.2	0.02	66 (100)	0.2
Traction therapy	683	63 (9.2)	0.2	<0.01	74 (10.8)	0.2
Spinal fusion	378	60 (15.9)	0.2	0.02	65 (17.2)	0.2
Endoscopy in adults <55	1604	58 (3.6)	0.2	0.02	60 (3.7)	0.2
PTH testing	6251	53 (0.8)	0.2	0.01	58 (0.9)	0.2
Electroencephalography	4266	40 (0.9)	0.1	0.01	117 (2.7)	0.3
1,25-dihydroxyvitamin D testing	474	28 (5.9)	0.1	0.01	28 (5.9)	0.1
Vertebroplasty	61	27 (44.3)	0.1	0.01	30 (49.2)	0.1
IVC filters	30	26 (86.7)	0.1	0.01	26 (86.7)	0.1
Endotoxin apheresis	25	25 (100)	0.1	0.01	25 (100)	0.1
Artificial liver support	27	18 (66.7)	0.1	0.01	18 (66.7)	0.1
PAC	295	12 (4.1)	0.03	<0.01	12 (4.1)	0.03
Arthroscopic surgery	77	8 (10.4)	0.02	<0.01	40 (51.9)	0.1
Renal angioplasty	7	6 (85.7)	0.02	<0.01	6 (85.7)	0.02
PCI	1660	2 (0.1)	0.01	<0.01	151 (9.1)	0.4
Intravenous anti-herpes drugs	338	1 (0.3)	<0.01	<0.01	2 (0.6)	0.01
Surgery for VUR in children	1	1 (100)	<0.01	<0.01	1 (100)	<0.01
Tricyclic antidepressants prescription in children	31	0 (0)	0	0	9 (29.0)	0.03

Continued

Table 1 Continued

Healthcare services	Narrower definition (high specificity)*			Broader definition (high sensitivity)*		
	No of episodes	No (%) of LVC episodes	No of LVC episodes/1000†	% of patients receiving LVC	No (%) of LVC episodes	No of LVC episodes/1000†
Carotid endarterectomy	22	0 (0)	0	0	6 (27.3)	0.02
Nasolacrimal probe in infants	0	0	0	0	0	0
Electroconvulsive therapy in children	0	0	0	0	0	0
Total	243722	39657 (16.3)	114.8	4.9‡	75638 (31.0)	218.9

*We developed two versions of each measure: a narrower definition (higher specificity and less misclassification of inappropriate use) and a broader definition (higher sensitivity and greater capture of inappropriate use).

†Denominator is the number of patients seeking care at an analytic acute care hospital at least once in the fiscal year 2019 (note that the same individual might be double-counted if he or she visited a different hospital).

‡Totals do not equal sums for the percentage of patients receiving each low-value service because some patients received multiple low-value services.

LVC, inferior vena cava; PAC, pulmonary artery catheterisation; PCI, percutaneous coronary intervention; PTH, parathyroid hormone; T3, triiodothyronine; VUR, vesicoureteral reflux.

the facts that our analytic sample was a 5% sample, and that our analytic hospitals accounted for approximately 11% of all discharges from acute care hospitals in Japan, simple extrapolation indicates that more than 3million patients experienced low-value care across all Japanese acute care hospitals in a given year. It was also found that at least 11 low-value episodes occurred per 100 patients in the year. The healthcare spending of low-value care accounted for at least 0.23% of the total annual medical healthcare spending across the analytic hospitals. A simple extrapolation to the JPY 44trillion of Japanese total medical spending in 2019³⁵ indicates at least JPY 100billion (approximately US\$ 1billion) of medical overuse every year, suggesting that low-value care consumes considerable resources in the Japanese universal healthcare system.

Overall, our finding that 4.9% of all patients seeking care at hospitals received low-value care was comparable to the figure of 5% reported in Alberta, Canada¹⁰ and 8% reported in the USA,⁶ even though making direct comparisons is difficult because not all of the low-value services measured overlap. Our findings extend previous studies by demonstrating that low-value care is an important policy issue as well in Japan and suggesting that there is room for reducing the burden of low-value care even under a universal social insurance system.

As a whole, there was no evidence of a clear decline in the prevalence of low-value services in Japanese acute care hospitals between 2015 and 2019, despite the increasing awareness of low-value care and its associated harms in Japan.^{36 37} This is similar to the findings in the USA, which showed that low-value care use remained similar or declined only slightly over time even after the Choosing Wisely campaign,^{38–40} although the measurement methods, timing and target population were different.

Consistent with prior studies, trends in the prevalence of low-value care varied by individual service.^{11 38} Five services with high frequency and increasing trends (eg, serum T3 level testing and pregabalin prescriptions) should be prioritised for further investigation to understand the drivers behind these increases and the possible solutions to reduce their low-value care use. For 16 low-value services that were already rare (eg, renal angioplasty and arthroscopic surgery for knee osteoarthritis) and 6 services with downward trends, background monitoring will be helpful in identifying changes in trends early. The decreasing trends of oral/intravenous betamimetics use and traction therapy for neck/back pain may reflect changes in recommendations in the Japanese Society of Obstetrics and Gynecology Guideline in 2014⁴¹ and the Japanese Society of Orthopaedic Association Guideline in 2012.⁴² Moreover, decreased low-value antibiotic prescribing for the common cold is encouraging, given the growing global and national attention focused on antibiotic stewardship and appropriate antibiotic prescribing. This was in contrast to the stable trend in antibiotic consumption from 2004 to 2016 in Japan.⁴³ In response to this trend, the Japanese government in 2016 introduced a policy goal to reduce the use of antibiotics by two-thirds by 2020. In pursuit

Table 2 Healthcare spending of low-value care for 33 healthcare services in the fiscal year 2019

Low-value services	Narrower definition		Broader definition	
	Total healthcare spending, * JPY (millions)	% of overall healthcare spending	Total healthcare spending, * JPY (millions)	% of overall healthcare spending
Antibiotics prescription for common cold ⁵⁰	196.0	0.01	253.3	0.01
Serum T3 level testing for hypothyroidism ⁹	209.6	0.01	209.6	0.01
Pregabalin prescription for back pain ^{51 52}	605.0	0.02	3473.6	0.14
Spinal injection for low back pain ⁹	1733.8	0.07	1760.2	0.07
Oral betamimetics prescription ⁵³	61.3	0.002	61.3	0.002
Preoperative pulmonary function testing ⁹	119.0	0.01	119.2	0.01
Preoperative echocardiogram ⁹	252.7	0.01	253.8	0.01
Bone mineral density testing at frequent intervals ^{9 10}	84.0	0.003	431.0	0.02
Hypercoagulability testing for patients with deep vein thrombosis ^{9 10}	21.8	0.001	23.4	0.001
Intravenous betamimetics for inhibiting preterm labour, >48 hours ⁵⁴	101.9	0.004	101.9	0.004
Preoperative stress testing or stress testing for stable coronary disease ^{9 10}	49.8	0.002	930.5	0.04
Preoperative breast MRI ⁵⁵	46.5	0.002	49.9	0.002
Intravenous sivelestat for acute respiratory disease syndrome ^{56 57}	52.0	0.002	52.0	0.002
Traction therapy for back pain or neck pain ⁵⁸⁻⁶⁰	0.4	<0.001	0.5	<0.001
Spinal fusion for lumbar stenosis ^{11 61}	1038.2	0.04	1184.6	0.05
Endoscopy for dyspepsia for people <55 years or colonoscopy for constipation in people <50 years ¹¹	40.6	0.002	41.2	0.002
PTH testing for patients with stages 1–3 chronic kidney disease ⁹	1.9	<0.001	2.0	<0.001
Electroencephalography for headache ⁹	6.4	<0.001	19.7	0.001
1,25-dihydroxyvitamin D testing in the absence of hypercalcemia or decreased kidney function ⁹	2.2	<0.001	2.2	<0.001
Vertebroplasty for osteoporotic vertebral fractures ^{9 11}	459.3	0.02	525.8	0.02
Inferior vena cava (IVC) filters for the prevention of pulmonary embolism ⁹	118.6	0.01	118.6	0.01
Endotoxin apheresis for sepsis ^{62 63}	297.1	0.01	297.1	0.01
Artificial liver support for acute liver failure ⁶⁴	10.8	<0.001	10.8	<0.001
PAC in the ICU ⁹	5.9	<0.001	5.9	<0.001
Arthroscopic surgery for knee osteoarthritis ^{9 11}	68.5	0.003	288.0	0.01
Renal angioplasty ^{9 11}	89.9	0.004	89.9	0.004
PCI with angioplasty or stent placement for stable coronary disease ⁹	26.7	0.001	2454.5	0.10
Intravenous anti-herpes drugs for sudden sensorineural hearing loss ⁶⁵	0.1	<0.001	0.3	<0.001
Surgery for vesicoureteral reflux ¹¹	8.1	<0.001	8.1	<0.001
Tricyclic antidepressants prescription for children without other psychological disorders ⁶⁶	0	0	0.1	<0.001
Carotid endarterectomy in asymptomatic patients ^{9 11}	0	0	92.1	0.004
Nasolacrimal probe in infants ¹¹	0	0	0	0
Electroconvulsive therapy in children ¹¹	0	0	0	0
Total	5708.3	0.23	12 861.3	0.51

*The healthcare spending was calculated based on a fee-for-service method. Healthcare spending on services was multiplied by 20 to approximate the healthcare spending for the entire patient population from 5% samples.

ICU, intensive care unit; JPY, Japanese yen (110 JPY=1US\$ and 140 JPY=1 British pound); PAC, pulmonary artery catheterisation; PCI, percutaneous coronary intervention; PTH, parathyroid hormone; T3, triiodothyronine.




Figure 1 Total number of low-value episodes per 1000 patients: fiscal year 2015–2019. Among the 33 identified low-value services, we evaluated the aggregated number of 31 low-value services that were measurable throughout the period, except for bone mineral testing (measurable from FY2017) and breast MRI (measurable from FY2016).

of this goal, Japan has successfully promoted the education of physicians, the financial incentive for not prescribing antibiotics to children and public awareness campaigns using posters.⁴⁴ In a similar vein to a previous study that showed how the trend of antibiotics prescribing was influenced by this nationwide policy,⁴⁵ our findings suggest the possibility that bolstering and combining such supply-side and demand-side interventions may work to reduce low-value care. However, our finding contrasts with studies in the USA that showed recent stable or increasing trends in inappropriate antibiotic prescribing,^{38 46} meaning that further investigations are needed to understand how and why the effect




Figure 2 Number of low-value episodes per 1000 patients for 17 common low-value services: fiscal year 2015–2019. We focused on 17 healthcare services, with most episodes involving low-value care (narrower definition) in the fiscal year 2019. PTH, parathyroid hormone; T3, triiodothyronine.

of global initiatives to reduce low-value care may differ by country.

Patient characteristics such as age, gender and Charlson's score were associated with the risk of receiving low-value care. For example, in the case of antibiotics for the common cold, physicians may be more defensive to patients who have more complications and, as a result, may be more likely to prescribe unnecessary antibiotics. Akin to a previous study in Canada, however, the associations with age and Charlson's score were inconsistent across services. We also found that the probability of receiving low-value care differed depending on hospital characteristics. The inconsistent direction of association with hospital size across services suggests the importance of measurement and reporting of specific low-value services at the hospital level.⁴⁷ The variations in low-value care frequencies across healthcare organisations were similarly reported in previous studies in the USA.^{8 47 48} Our study extends those findings by suggesting that provider-level drivers influence the overuse of individual low-value care even in the Japanese health insurance system strictly regulated by the government. Do to the lack of data, other provider-level characteristics including hospital ownership, location and teaching status, were not assessed in the current study. Further studies are needed to evaluate structural hospital characteristics associated with the provision of low-value care. For example, private hospitals, which account for approximately 80% of total hospitals in Japan,⁴⁹ may have stronger incentives to provide profitable health services, including low-value services.

Our study has several limitations. First, although we investigated as many as 33 measures of low-value care, identified based on solid clinical evidence, we did not consider other possible inappropriate care. For example, we could not capture services beyond the coverage of the Japanese health insurance system. Further research investigating more kinds of evidence-based low-value care will help to improve the understanding of low-value care provision in Japan. In addition, we did not capture downstream effects caused by inappropriate care, such as healthcare spending on adverse events and complications associated with low-value care. Despite these limitations, our estimates suggest that low-value services in Japan are substantial. Second, as with any direct low-value care measurement studies, our estimates were limited by using claims data. The claims data can precisely capture whether procedures are provided but do not include detailed clinical information of the sort that is often required to determine the appropriateness of the procedures, which is in contrast to medical record data. In selecting low-value care recommendations, we emphasised specificity with which overuse could be identified to address this uncertainty. We also reported the narrower and broader definitions with different sensitivity and specificity, following the methods used in previous studies.⁷ Despite these limitations, claims-based measurement of low-value care could be performed at less cost than medical record data and is helpful for continuous monitoring and payment policy. Validation of claims-based measurement of low-value care using medical records as a gold standard would be

Table 3 Association between patient characteristics and probability of receiving low-value care (narrower definition) for adults aged ≥ 18 in the fiscal year (FY) 2019

	Adjusted OR (95% CI)				
	At least one of the 33 low-value services	Antibiotics prescription for the common cold	Serum T3 level testing for hypothyroidism	Spinal injection for low back pain	Spinal fusion for lumbar stenosis
Patients' age (every 10 years)	0.90*** (0.90 to 0.91)	0.75*** (0.74 to 0.76)	1.03** (1.01 to 1.06)	1.30*** (1.26 to 1.34)	1.43*** (1.28 to 1.61)
Patients' sex (reference: male)					
Female	1.37*** (1.32 to 1.41)	1.02 (0.96 to 1.08)	1.74*** (1.60 to 1.88)	1.06 (0.95 to 1.19)	1.04 (0.62 to 1.73)
Charlson's comorbidity score (reference: 0–1)					
2–4	1.51*** (1.45 to 1.57)	1.49*** (1.38 to 1.60)	2.73*** (2.50 to 2.98)	0.68*** (0.59 to 0.79)	0.54 (0.27 to 1.08)
5+	2.45*** (2.29 to 2.63)	2.61*** (2.31 to 2.96)	6.04*** (5.35 to 6.82)	0.96 (0.74 to 1.26)	0.59 (0.14 to 2.42)
Size of treating hospital (reference: small)					
Medium	0.82*** (0.78 to 0.86)	0.60*** (0.55 to 0.64)	1.16 (0.99 to 1.35)	0.45*** (0.39 to 0.51)	1.10 (0.43 to 2.84)
Large	0.73*** (0.69 to 0.77)	0.37*** (0.34 to 0.41)	1.53*** (1.31 to 1.78)	0.31*** (0.26 to 0.37)	1.53 (0.58 to 4.01)

The size of the treating hospital was categorised according to the number of beds as follows: small (<200 beds), medium (200–499 beds) and large (≥ 500 beds). After excluding 10945 patients (3.6%) who had missing data on comorbidities, we analysed 292275 adult patients seeking care at an analytic acute care hospital, including outpatient and/or inpatient services, at least once in FY2019 (note that the same individual might be double-counted if he or she visited a different hospital). We regressed the indicator of receiving at least one of the 33 low-value services in FY2019 on the patient characteristics (age, sex and Charlson's comorbidity score at the first visit of FY2019) and treating hospital size by using logistic regression with Huber-White robust standard errors. We similarly calculated the OR for receiving each of the four selected low-value services at least once in the year in the same manner. Antibiotics prescription for common cold and T3 level testing for hypothyroidism are the two services with most episodes involving low-value care (narrower definition), and spinal injection for low back pain and spinal fusion for lumbar stenosis are the two services accounting for the greatest healthcare spending in FY2019.

** $P < 0.01$, *** $p < 0.001$.

T3, triiodothyronine.

needed to elucidate the relative strengths and weaknesses of claims-based measurement. Finally, while the patient population covered acute care hospitals, it did not examine other medical facilities, such as outpatient clinics, non-acute care hospitals and nursing homes. Patients treated in these facilities may have different patterns in receiving low-value care and thus warrant further investigation.

CONCLUSION

Our claims-based measurement of low-value care revealed that a substantial number of patients were receiving low-value care in Japan. The overall trend in low-value care use remained similar or declined only slightly over time, despite increasing awareness of waste of healthcare spending in Japan. Identifying and measuring low-value care is an essential step in reducing it, and it is hoped that close collaboration with clinicians and policymakers will improve the indicators of low-value care developed in this study or add new ones.

Author affiliations

¹Division of General Internal Medicine and Health Services Research, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA

²Department of Public Health, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan

³Department of Epidemiology, University of California Los Angeles Jonathan and Karin Fielding School of Public Health, Los Angeles, California, USA

⁴Tokyo Foundation for Policy Research, Minato-ku, Tokyo, Japan

⁵Muribushi Okinawa Center for Teaching Hospitals, Urasoe, Okinawa, Japan

⁶Graduate School of Business Administration, Keio University, Yokohama, Kanagawa, Japan

⁷Department of Health Policy and Management, University of California Los Angeles Jonathan and Karin Fielding School of Public Health, Los Angeles, California, USA

Twitter Atsushi Miyawaki @AMiyawaki38, Ryo Ikesu @IkesuRyo, Yasuharu Tokuda @yasuharutokuda and Yusuke Tsugawa @ytsugawa1

Acknowledgements The authors would like to acknowledge the contribution of the following team of specialist physicians who worked hard to develop a candidate list of low-value services by reviewing and evaluating the clinical evidence based on the peer-reviewed medical literature. The team members are as follows: respiratory medicine: Dr Ken Saraya; gastroenterology: Dr Susumu Shinoura; cardiology: Dr Atsushi Mizuno; nephrology: Dr Takuhiro Moromizato; primary care: Dr Yuki Kaji; infectious disease: Dr Hitoshi Honda; haematology: Dr Shotaro Hagiwara; oncology: Dr Noriyuki Katsumata; endocrine disorders: Dr Hiroshi Noto; psychiatry: Dr Takao Kanai; preventive medicine: Dr Makito Yaegashi; digestive surgery: Dr Kazuhiro Hiyama; breast surgery: Dr Yasuaki Sagara; urology: Dr Masayoshi Zaitus; orthopaedics: Dr Masashi Nagao; ophthalmology: Dr Masahiro Miyake; otolaryngology: Dr Takashi Fujiwara; Anesthesiology: Dr Yasuko Nagasaka and Dr Aya Sakano; intensive care: Dr Yushihiro Norisue; emergency medicine: Dr Takashi Shiga; Paediatric surgery: Dr Keigo Yada; obstetrics and gynaecology: Dr Ayako Shibata; rehabilitation: Dr Hidetaka Wakabayashi; radiology: Dr Kanako Kumamaru; pathology: Dr Ken Kuriki; dermatology: Dr Hideki Koketsu. We would also like to thank other specialty physicians (Dr Jun Gotoh, Dr Toshihiro Tanaka and Dr Madoka Nakajima) for taking the time to evaluate clinical evidence.

Contributors AM contributed to conceptualisation, formal analysis, funding acquisition, methodology, visualisation, project administration, resources, writing—original draft. RI contributed to methodology, software, writing—review & editing. YTo contributed to conceptualisation, methodology, project administration, resources, writing—review & editing. RG contributed to conceptualisation, methodology, project administration, resources, writing—review & editing. YK contributed to supervision, writing—review & editing. KS contributed to methodology, software, writing—review & editing. YTs contributed to conceptualisation, methodology, project administration, resources, supervision, writing—review & editing. AM is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding AM was funded primarily by a grant from the Abe Fellowship Program administered by the Social Science Research Council in cooperation with and with funds provided by the Japan Foundation Center for Global Partnership (grant number is not applicable). Additional partial support was provided by the Japan Society for the Promotion of Science (20K18956). The findings and conclusions of this article are the sole responsibility of the authors and do not represent the official views of the research funders.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. We obtained the data from the Medical Data Vision Co. (MDV), and we are not allowed to share these data with other parties. However, researchers who meet the criteria for access can acquire de-identified participant data from the MDV (<https://en.mdv.co.jp>).

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Atsushi Miyawaki <http://orcid.org/0000-0001-6126-1464>

Yasuharu Tokuda <http://orcid.org/0000-0002-9325-7934>

Yusuke Tsugawa <http://orcid.org/0000-0002-1937-4833>

REFERENCES

- Maratt JK, Kerr EA, Klamers ML, *et al.* Measures used to assess the impact of interventions to reduce low-value care: a systematic review. *J Gen Intern Med* 2019;34:1857–64.
- OECD. Tackling Wasteful spending on health, 2017. Available: <https://www.oecd-ilibrary.org/content/publication/9789264266414-en>
- Brownlee S, Chalkidou K, Doust J, *et al.* Evidence for overuse of medical services around the world. *Lancet* 2017;390:156–68.
- ABIM Foundation. Choosing wisely. An initiative of the ABIM Foundation, 2021. Available: <https://www.choosingwisely.org> [Accessed 10 Jul 2022].
- Levinson W, Born K, Wolfson D. Choosing wisely campaigns: a work in progress. *JAMA* 2018;319:1975–6.
- Reid RO, Rabideau B, Sood N. Low-Value health care services in a commercially insured population. *JAMA Intern Med* 2016;176:1567–71.
- Schwartz AL, Landon BE, Elshaug AG, *et al.* Measuring low-value care in Medicare. *JAMA Intern Med* 2014;174:1067–76.
- Schwartz AL, Jena AB, Zaslavsky AM, *et al.* Analysis of physician variation in provision of low-value services. *JAMA Intern Med* 2019;179:125.
- Schwartz AL, Chernew ME, Landon BE, *et al.* Changes in low-value services in year 1 of the Medicare pioneer accountable care organization program. *JAMA Intern Med* 2015;175:1815–25.
- McAlister FA, Lin M, Bakal J, *et al.* Frequency of low-value care in Alberta, Canada: a retrospective cohort study. *BMJ Qual Saf* 2018;27:340–6.
- Badgery-Parker T, Pearson S-A, Chalmers K, *et al.* Low-Value care in Australian public hospitals: prevalence and trends over time. *BMJ Qual Saf* 2019;28:205–14.
- Badgery-Parker T, Pearson S-A, Elshaug AG. Hospital characteristics associated with low-value care in public hospitals in New South Wales, Australia. *BMC Health Serv Res* 2020;20:750.
- Chalmers K, Pearson S-A, Badgery-Parker T, *et al.* Measuring 21 low-value Hospital procedures: claims analysis of Australian private health insurance data (2010–2014). *BMJ Open* 2019;9:e024142.
- Sprenger M, Robausch M, Moser A. Quantifying low-value services by using routine data from Austrian primary care. *Eur J Public Health* 2016;26:912–6.
- Kool RB, Verkerk EW, Meijis J, *et al.* Assessing volume and variation of low-value care practices in the Netherlands. *Eur J Public Health* 2020;30:236–40.
- Commonwealth Fund. International profiles of health care systems. Available: https://www.commonwealthfund.org/sites/default/files/2020-12/International_Profiles_of_Health_Care_Systems_Dec2020.pdf [Accessed 10 Jul 2022].
- Levinson W, Kallewaard M, Bhatia RS, *et al.* 'Choosing wisely': a growing international campaign. *BMJ Qual Saf* 2015;24:167–74.
- Kobayashi Y. Five decades of universal health insurance coverage in Japan: lessons and future challenges. *JMAJ* 2009;52:263–8 https://www.med.or.jp/english/journal/pdf/2009_04/263_268.pdf
- Ikegami N, Yoo B-K, Hashimoto H, *et al.* Japanese universal health coverage: evolution, achievements, and challenges. *The Lancet* 2011;378:1106–15.
- Medical data vision Co., Ltd. MDV database. Available: <https://en.mdv.co.jp> [Accessed 10 Jul 2022].
- Nakamura M. Utilization of MDV data and data quality control. *Jpn J Pharmacoepidemiol* 2016;21:23–5.
- Miyawaki A, Tomio J, Nakamura M, *et al.* Changes in surgeries and therapeutic procedures during the COVID-19 outbreak: a longitudinal study of acute care hospitals in Japan. *Ann Surg* 2021;273:e132–4.
- Maeda Y, Nakamura M, Ninomiya H, *et al.* Trends in intensive neonatal care during the COVID-19 outbreak in Japan. *Arch Dis Child Fetal Neonatal Ed* 2021;106:327–9.
- Taniguchi Y, Kuno T, Koriyama J, *et al.* Comparison of patient characteristics and in-hospital mortality between patients with COVID-19 in 2020 and those with influenza in 2017–2020: a multicenter, retrospective cohort study in Japan. *Lancet Reg Health West Pac* 2022;20:100365.
- Nishikawa A, Yoshinaga E, Nakamura M, *et al.* Validation study of algorithms to identify malignant tumors and serious infections in a Japanese administrative healthcare database. *ACE* 2022;4:20–31.
- Ministry of Health Labour and Welfare. Patient survey, 2017. Available: <https://www.mhlw.go.jp/toukei/saikin/hw/kanja/17/index.html> [Accessed 10 Jul 2022].
- Choosing wisely Canada. Available: <https://choosingwiselycanada.org> [Accessed 10 Jul 2022].
- Choosing wisely UK. Available: <https://www.choosingwisely.co.uk> [Accessed 10 Jul 2022].
- Choosing Wisely Australia. Tests, treatments, and procedures for healthcare providers and consumers to question. Recommendations, 2019. Available: <http://www.choosingwisely.org.au/recommendations> [Accessed 10 Jul 2022].
- US Preventive Services Task Force. Recommendations for primary care practice, 2019. Available: <https://www.uspreventiveservicestaskforce.org/Page/Name/recommendations> [Accessed 10 Jul 2022].
- Soon J, Buchbinder R, Close J, *et al.* Identifying low-value care: the Royal Australasian College of physicians' evolve initiative. *Med J Aust* 2016;204:180–1.
- World Health Organization. International statistical classification of diseases and related health problems 10th revision, 2016. Available: <http://apps.who.int/classifications/icd10/browse/2016/en> [Accessed 10 Jul 2022].
- Chalmers K, Pearson S-A, Elshaug AG. Quantifying low-value care: a patient-centric versus service-centric lens. *BMJ Qual Saf* 2017;26:855–8.
- Research team on cost-effectiveness evaluation (strategic integrated scientific research project). guideline for preparing cost-effectiveness evaluation to the central social insurance medical Council. center

- for outcomes research and economic evaluation for health, National Institute of public health, 2019. Available: https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf [Accessed 10 Jul 2022].
- 35 Ministry of Health Labour and Welfare. National health expenditure 2019, 2021. Available: <https://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/19/index.html> [Accessed 10 Jul 2022].
- 36 Tokuda Y. Current status of choosing wisely in Japan. *General Medicine* 2015;16:3–4.
- 37 Choosing Wisely Japan. Choosing wisely Japan. Available: <https://choosingwisely.jp> [Accessed 10 Jul 2022].
- 38 Mafi JN, Reid RO, Baseman LH, *et al.* Trends in low-value health service use and spending in the US Medicare fee-for-service program, 2014–2018. *JAMA Netw Open* 2021;4:e2037328.
- 39 Rosenberg A, Agiro A, Gottlieb M, *et al.* Early trends among seven recommendations from the choosing wisely campaign. *JAMA Intern Med* 2015;175:175.
- 40 Park S, Jung J, Burke RE, *et al.* Trends in use of low-value care in traditional fee-for-service Medicare and Medicare advantage. *JAMA Netw Open* 2021;4:e211762.
- 41 Japan Society of obstetrics and gynecology and Japanese association of obstetricians and Gynecologists. guidelines for obstetric care, 2014. Available: <http://www.jaog.or.jp/wp/wp-content/uploads/2017/01/img-31020320.pdf> [Accessed 10 Jul 2022].
- 42 The Japanese Orthopaedic association and Japanese Society of lumbar spine disorders. guidelines for treatment of low back pain, 2012. Available: <https://minds.jcqh.or.jp/n/med/4/med0021/G0000533/0001> [Accessed 10 Jul 2022].
- 43 Tsutsui A, Yahara K, Shibayama K. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. *J Infect Chemother* 2018;24:414–21.
- 44 The government of Japan. National action plan on antimicrobial resistance (AMR), 2016. Available: <https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000138942.pdf> [Accessed 10 Jul 2022].
- 45 Kusama Y, Tsuzuki S, Muraki Y, *et al.* The effects of Japan's National action plan on antimicrobial resistance on antimicrobial use. *Int J Infect Dis* 2021;103:154–6.
- 46 Barnett ML, Linder JA. Antibiotic prescribing to adults with sore throat in the United States, 1997–2010. *JAMA Intern Med* 2014;174:138–40.
- 47 Ganguli I, Morden NE, Yang C-WW, *et al.* Low-Value care at the actionable level of individual health systems. *JAMA Intern Med* 2021;181:1490–500.
- 48 Mafi JN, Wee CC, Davis RB, *et al.* Association of primary care practice location and ownership with the provision of low-value care in the United States. *JAMA Intern Med* 2017;177:838–45.
- 49 Ikegami N. Japan: achieving UHC by regulating payment. *Global Health* 2019;15:72.
- 50 Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. *Cochrane Database Syst Rev* 2013:CD000247.
- 51 Mathieson S, Maher CG, McLachlan AJ, *et al.* Trial of pregabalin for acute and chronic sciatica. *N Engl J Med* 2017;376:1111–20.
- 52 Enke O, New HA, New CH, *et al.* Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. *CMAJ* 2018;190:E786–93.
- 53 Dodd JM, Crowther CA, Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. *Cochrane Database Syst Rev* 2012;12:CD003927.
- 54 Neilson JP, West HM, Dowswell T. Betamimetics for inhibiting preterm labour. *Cochrane Database Syst Rev* 2014:CD004352.
- 55 Houssami N, Turner R, Macaskill P, *et al.* An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. *J Clin Oncol* 2014;32:392–401.
- 56 Vincent J-L, Francois B, Zabolotskikh I, *et al.* Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the scarlet randomized clinical trial. *JAMA* 2019;321:1993–2002.
- 57 Iwata K, Doi A, Ohji G, *et al.* Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. *Intern Med* 2010;49:2423–32.
- 58 Clarke JA, van Tulder MW, Blomberg SEI, *et al.* Traction for low-back pain with or without sciatica. *Cochrane Database Syst Rev* 2007:CD003010.
- 59 Yang J-D, Tam K-W, Huang T-W, *et al.* Intermittent cervical traction for treating neck pain: a meta-analysis of randomized controlled trials. *Spine* 2017;42:959–65.
- 60 Graham N, Gross A, Goldsmith CH, *et al.* Mechanical traction for neck pain with or without radiculopathy. *Cochrane Database Syst Rev* 2008:CD006408.
- 61 Försth P, Ölafsson G, Carlsson T, *et al.* A randomized, controlled trial of fusion surgery for lumbar spinal stenosis. *N Engl J Med* 2016;374:1413–23.
- 62 Evans L, Rhodes A, Alhazzani W, *et al.* Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med* 2021;47:1181–247.
- 63 Egi M, Ogura H, Yatabe T, *et al.* The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020). *J Intensive Care* 2021;9:53.
- 64 Liu JP, Gluud LL, Als-Nielsen B, *et al.* Artificial and bioartificial support systems for liver failure. *Cochrane Database Syst Rev* 2004:CD003628.
- 65 Awad Z, Huins C, Pothier DD. Antivirals for idiopathic sudden sensorineural hearing loss. *Cochrane Database Syst Rev* 2012:CD006987.
- 66 Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. *Cochrane Database Syst Rev* 2013:CD002317.

Appendices

Prevalence and Changes of Low-Value Care at Acute Care Hospitals: A Multi-Center Observational Study in Japan

Supplementary Figure 1. Comparison of discharged patients' characteristics between the Patient Survey (=nationwide representative survey) vs. the hospital claims data used in our study

Supplementary Method 1. Quality controls of the database

Supplementary Method 2. Identification of measurable low-value services

Supplementary Table 1. Clinical specialty areas of expert board

Supplementary Figure 2. Overall summary of the study

Supplementary Table 2. Operational definitions of low-value care for each healthcare service

Supplementary Table 3. Codes for measures of low-value services


Supplementary Table 4. Change of total number of low-value episodes per 1,000 hospital patients from fiscal year (FY) 2015 to 2019

Supplementary Table 5. Change of low-value episodes per 1,000 hospital patients from fiscal year (FY) 2015 to 2019 for 17 healthcare services with most episodes involving low-value care (narrower definition) in FY 2019

Supplementary Figure 3. Number of low-value episodes per 1,000 patients seeking care, using the broader definition

Supplementary Table 6. Crude probability of receiving at least one of the 33 low-value services in the fiscal year 2019 among adult patients, by patient and hospital characteristics

Supplementary Figure 1. Comparison of discharged patients’ characteristics between the Patient Survey (=nationwide representative survey) vs. the hospital claims data used in our study



The figure shows that the distributions of age, sex, and the principal diagnosis of patients discharged from acute care hospitals were similar between the nationwide estimates from the Patient Survey and those from the analytic hospitals in our data.

Supplementary Method 1. Quality controls of the database

The MDV claims database used in this study was collected in two steps. First, all the electronic claims data accumulated in target acute care hospitals are sent to the MDV after de-identification. Since electronic claims data are recorded for billing purposes in Japanese hospitals, all patients treated at a given hospital are included in the data. Then, they are imported into the database by data managers. Quality assessments of the data accuracy are performed as follows:

- (a) Systematic errors during data registration at the hospital (e.g., errors due to changes in the in-hospital system) are checked and corrected after confirmation with the hospital.
- (b) All claims data, including inpatient, outpatient, and prescription claims, are automatically investigated for abnormal values by comparing those to the previous month, the same month of the previous year. When an abnormal value is found, the data manager confirms it with the target hospital and request the hospital to resubmit the data if there is an error in the submitted data.
- (c) Diagnosis and drug names are standardized into the International Classification of Diseases, Tenth Revision (ICD-10), and the Anatomical Therapeutic Chemical code using the master files. For disease names that have not been coded (freely described disease names), a uniquely developed matching dictionary between disease names and ICD-10 codes is applied and coded.

As for the completeness and accuracy of the MDV claims data, a study using physician medical record review as the gold standard in two hospitals participating in the MDV database reported that MDV claims data were able to identify cases of malignant tumors and severe infections with good positive predictive value and sensitivity.¹

Supplementary Method 2. Identification of measurable low-value services

We first listed up 68 low-value services measured in previous seminal work in the US (Schwarz et al., 2015), Canada (Mcalister et al., 2018), and Australia (Badgery-Parker et al., 2019). Then, to identify low-value services not included in these studies and/or low-value services potentially unique to Japan, we conducted a literature review based on the candidates of low-value care picked up by the expert group in a predetermined process.

In this process, we began by assembling an specialist physicians board from as many clinical specialty areas as possible. The specialists were selected by the author group based on experience in their specialty, gender, and geographical location (by purposive sampling). We asked the selected specialists to review the clinical evidence to create a list of as many potentially low-value services as possible in their specialty area (allowing overlap) based on the peer-reviewed medical literature. The experts were also asked to judge the evidence level and categorized each service into the following three groups:

- (1) Definitely low-value (there is evidence that it has no clinical benefit, namely the service has been concluded to be "having no effect" in multiple randomized controlled trials or meta-analyses.)
- (2) Unclear (There is no evidence that it has clinical benefit, or evidence is mixed)
- (3) Definitely effective (there is evidence that it has clinical benefit).

We contacted physicians in 31 specialties and finally obtained responses from physicians in 26 specialties (**Supplementary Table 1**). The specialists presented a total of 209 low-value services candidates.

Next, for each potentially low-value service listed by the specialists, physicians independent of the expert group (AM, RI, and KS in the author group) repeated the literature review and categorization process based on the clinical evidence in the same manner as described above.

Then, we selected those consistently categorized as "definitely low-value" by both specialists and independent physicians as low-value care. Among the 209 low-value medical candidates, 45 services were categorized as "definitely low-value" by specialists and independent physicians.


Finally, we combined the listed items from the seminal work and our literature review and identified 113 (68+45) recommendations. After we excluded duplicated recommendations, we selected low-value services measurable in the Japanese hospital claims data. Whether or not the service is measurable in claims data was determined by three physicians with sufficient experience in claims data analyses (AM, RI, and YT). The selection criteria were (1) being recorded in the hospital claims data under the Japanese health insurance system and (2) being possible to reasonably identify a low-value episode using the variables in the data with high specificity. Unmeasurable services included those for which there was insufficient information in the claims data to identify (e.g., head imaging for syncope and uncomplicated headache and back imaging for low back pain), and those that were not covered by Japanese public health insurance (services related to preventive care, pregnancy checkups, and regular deliveries, e.g., prostate cancer screening by prostate-specific antigen).

After excluding 22 duplicated recommendations and 58 unmeasurable recommendations, 33 services (**Supplementary Table 2**) were identified as measurable low-value services.

Supplementary Table 1. Clinical specialty areas of expert board

Specialty Area
Respiratory medicine
Gastroenterology
Cardiology
Nephrology
Primary care
Infectious disease
Hematology
Oncology
Endocrine disorders
Psychiatry
Preventive medicine
Digestive surgery
Breast surgery
Urology
Orthopedics
Ophthalmology
Otolaryngology
Anesthesiology
Intensive care
Emergency medicine
Pediatric surgery
Obstetrics and gynecology
Rehabilitation
Radiology
Pathology
Dermatology

Supplementary Figure 2. Overall summary of the study



Negligible low-value care was defined as the below-median number of low-value services (narrower definition) for the 33 services (see Table 1). Trends are determined by calculating the average annual percentage change.

Supplementary Table 2. Operational definitions of low-value care for each healthcare service

Healthcare services (recommendation sources)	Service denominator	Numerator	
		Broader low-value care definition (Base definition)	Narrower low-value care definition (Additional restrictions)
Antibiotics prescription for the common cold (literature review)	Any oral antibiotics prescription	Oral antibiotics prescription for patients with a diagnosis of common cold	No diagnosis of pneumonia, bacterial bronchitis, otitis media, peritonsillar abscess, croup and epiglottitis, streptococcus pharyngitis, or chronic pharyngitis No hospitalization in the same month
Serum T3 level testing for patients with hypothyroidism (Schwarz et al., 2015)	Any total or free T3 test	Total or free T3 measurement in a patient with a hypothyroidism diagnosis sometimes that calendar year	- ^a
Pregabalin prescription for back pain (literature review)	Any pregabalin prescription	Pregabalin prescription in a patient with the diagnosis of back pain	Pregabalin prescription in a patient with the diagnosis of back pain (except for patients with a diagnosis of fibromyalgia, diabetes, postherpetic neuralgia, arteriosclerosis, disc disorder, trigeminal neuralgia, or peripheral neuropathy)
Spinal injection for low back pain (Schwarz et al., 2015)	Any outpatient spinal injection in adults aged ≥ 18	Epidural (not indwelling), facet, or trigger point injections in a patient with a diagnosis of lower back pain in the same month, not associated with an inpatient stay (within 14 days)	No diagnoses indicating radiculopathy in the claim in the same month
Oral betamimetics prescription (literature review)	Any oral betamimetics prescription	Any oral betamimetics prescription	- ^a
Preoperative pulmonary function testing (PFT) (Schwarz et al., 2015)	Any outpatient PFT in adults aged ≥ 18	PFT occurring within 30 days prior to a low or intermediate-risk surgical procedure (selected surgeries ^b)	No PFTs related to off-hour visits
Preoperative echocardiogram (Schwarz et al., 2015)	Any outpatient echocardiograms in adults aged ≥ 18	Echocardiogram occurring within 30 days prior to a low or intermediate risk non-cardiothoracic surgical procedure (selected surgeries ^c)	No echocardiograms related to off-hour visits
Bone mineral density testing at frequent intervals (Schwarz et al., 2015; Mcalister et al., 2018)	Any bone mineral density test	Bone mineral density test less than two years after a prior bone mineral density test ^d	Only patients with a diagnosis of osteoporosis prior to the initial bone mineral density test
Hypercoagulability testing for patients with deep vein thrombosis (Schwarz et al., 2015; Mcalister et al., 2018)	Any lab tests for hypercoagulable states	Lab tests for hypercoagulable states within 30 days following the diagnosis of lower extremity deep vein thrombosis or pulmonary embolism	No evidence of recurrent thrombosis, defined by diagnosis of deep vein thrombosis or pulmonary embolism more than 90 days prior to claim
Intravenous betamimetics for inhibiting preterm labor, > 48h (literature review)	Any hospitalizations with intravenous betamimetics administration	Hospitalizations in which betamimetics intravenous infusion was administered for ≥ 3 days	- ^a
Preoperative stress testing or stress testing for stable coronary disease (Schwarz et al., 2015; Mcalister et al., 2018)	Any outpatient stress electrocardiogram, echocardiogram, nuclear medicine imaging, cardiac MRI, or CT angiography in adults aged ≥ 18	1) Stress test occurring within 30 days prior to a low or intermediate risk non-cardiothoracic surgical procedure (selected surgeries ^b) or 2) stress test in a patient with an established diagnosis of ischemic heart disease or angina (at least 6 months prior to the stress test)	Only patients with a diagnosis of myocardial infarction (ICD10: I21-I23) in order to exclude patients with a history of non-cardiac chest pain inaccurately coded as angina (i.e., those with no underlying ischemic heart disease who might benefit from screening and optimization of medical management)

		No stress test related to off-hour visits, which might be indicative of the acute coronary syndrome	
Preoperative breast MRI (literature review)	Any breast MRI in adults aged ≥ 18	Breast MRI within 30 days prior to breast cancer surgery ^e	Only patients with no diagnosis of hereditary breast and ovarian cancer syndrome and breast Paget's disease, no surgery for benign breast diseases within 3 months, and no diagnosis of breast cancer more than 12 months prior to the MRI (to include only primary breast cancer)
Intravenous sivelestat for acute respiratory disease syndrome (literature review)	Any hospitalizations with intravenous sivelestat administration	Any hospitalizations with intravenous sivelestat administration	- ^a
Traction therapy for back pain or neck pain (literature review)	Any traction therapy in adults aged ≥ 18	Traction therapy for a patient with a diagnosis related to back or neck pain.	Only patients without a diagnosis of malignant spinal tumor, rheumatoid arthritis, spondylitis, or osteoporosis.
Spinal fusion for lumbar stenosis ((Badgery-Parker et al., 2019; literature review)	Any hospitalizations with spinal fusion surgeries in adults aged ≥ 18	Spinal fusion surgeries for lumbar stenosis (identified in inpatient claims data)	Only patients without a diagnosis of spondylolisthesis, pain in the foot, radiculopathy, sciatica, or congenital malformations of the spine
Endoscopy for dyspepsia for people < 55 years or colonoscopy for constipation in people < 50 years (Badgery-Parker et al., 2019)	Any endoscopies (esophagogastroduodenoscopies and colonoscopies) in adults aged 18-54	1) Endoscopy in a person aged 18-54 with a diagnosis of dyspepsia or 2) colonoscopy in a person aged 18-49 with a diagnosis of constipation	1) Endoscopy in a person aged 18-54 with a diagnosis of dyspepsia and no diagnoses of dysphagia, anemia, weight loss, cancer of the digestive system or 2) colonoscopy in a person aged 18-49 with a diagnosis of constipation and no diagnoses of anemia, weight loss, cancer of the digestive system, or other diseases of the digestive system
PTH testing for patients with stage 1-3 chronic kidney disease (Schwarz et al., 2015)	Any PTH testing	PTH measurement in patients with chronic kidney disease, without dialysis services in any of the same FY claims	No hypercalcemia diagnosis in any of the same FY claims
Electroencephalography (EEG) for headache (Schwarz et al., 2015)	Any outpatient EEG	EEG with headache diagnosis in the claim	No epilepsy or convulsions in the claims
1, 25-dihydroxy vitamin D testing in the absence of hypercalcemia or decreased kidney function (Schwarz et al., 2015)	Any calcitriol testing in adults aged ≥ 18	Calcitriol testing for patients without hypercalcemia or secondary hyperparathyroidism was noted in the claim, and without a history of CKD	No diagnoses indicating non-PTH mediated hypercalcemia (sarcoidosis, tuberculosis, and selected neoplasms)
Vertebroplasty for osteoporotic vertebral fractures (Schwarz et al., 2015; Badgery-Parker et al., 2019)	Any vertebroplasty in adults aged ≥ 18	Vertebroplasty for vertebral fracture	No bone cancers, myeloma, or hemangioma were noted in the claim in the same month
Inferior vena cava (IVC) filters for the prevention of pulmonary embolism (Schwarz et al., 2015)	Any hospitalizations with IVC filter placement in adults aged ≥ 18	Hospitalizations with IVC filter placement in a patient with a diagnosis of deep vein thrombosis or pulmonary embolism	- ^a
Endotoxin apheresis for sepsis (literature review)	Any hospitalizations with endotoxin apheresis in adults aged ≥ 18	Hospitalizations with endotoxin apheresis	- ^a
Artificial liver support for acute liver failure (literature review)	Any hospitalizations with artificial liver support in adults aged ≥ 18	Hospitalizations with artificial liver support in a patient with a diagnosis of acute liver failure	Only hospitalizations without a diagnosis of chronic or subacute liver disease
Pulmonary artery catheterization (PAC) in the ICU (Schwarz et al., 2015)	Any hospitalizations with PAC in adults aged ≥ 18	PAC during an inpatient stay that involved an ICU but not surgical procedures	Exclude claims that involved pulmonary hypertension or cardiac tamponade

Arthroscopic surgery for knee osteoarthritis (Schwarz et al., 2015; Badgery-Parker et al., 2019; literature review)	Any arthroscopic debridement/chondroplasty of the knee in adults aged ≥ 18	Arthroscopic surgery of the knee with the diagnosis of osteoarthritis or chondromalacia in the claim	No meniscal tear noted in the claim
Renal angioplasty (Schwarz et al., 2015; Badgery-Parker et al., 2019; literature review)	Any renal angioplasty in adults aged ≥ 18	Any renal angioplasty	Only a patient with a diagnosis of renovascular hypertension or renal atherosclerosis, and no diagnosis of fibromuscular dysplasia of renal artery, in the claim
Percutaneous coronary intervention (PCI) with angioplasty or stent placement for stable coronary disease (Schwarz et al., 2015)	Any stent placement or balloon angioplasty in adults aged ≥ 18	Stent placement or balloon angioplasty for a patient with an established diagnosis of ischemic heart disease or angina (at least 6 months prior to the procedure) Procedure not associated with off-hour visit, which might be indicative of acute coronary syndrome Procedure not related to acute coronary syndrome	Only patients with a past diagnosis of myocardial infarction in order to exclude patients with a history of non-cardiac chest pain inaccurately coded as angina
Intravenous anti-herpes drugs for sudden sensorineural hearing loss (literature review)	Any hospitalizations with intravenous acyclovir administration	Hospitalizations with intravenous anti-herpes drugs administration for a patient with a diagnosis of sudden sensorineural hearing loss	Only patients without a diagnosis of herpes infections (herpes simplex virus or herpes zoster virus)
Surgery for vesicoureteral reflux (Badgery-Parker et al., 2019)	Any surgery for vesicoureteral reflux in children aged <12	Any surgery for vesicoureteral reflux	Only patients with vesicoureteral-reflux
Tricyclic antidepressants prescription for children without other psychological disorders (literature review)	Any tricyclic antidepressants prescription for children in children aged 6-18 years	Tricyclic antidepressants prescription for children with a diagnosis of depression	Tricyclic antidepressants prescription for children with a diagnosis of depression, and without other psychological disorders
Carotid endarterectomy in asymptomatic patients (Schwarz et al., 2015; Badgery-Parker et al., 2019)	Any carotid endarterectomy in adults aged ≥ 18	Carotid endarterectomy for a patient aged ≥ 75 without a diagnosis of stroke, transient ischemic attack TIA, retinal artery occlusion, or nervous and musculoskeletal symptoms. Exclude emergency admissions (identified in inpatient claims)	Only a patient with a history of acute myocardial infarction, chronic obstructive pulmonary disease, or alcohol related disorder, with dialysis services, with presence of cardiac pacemaker, or aged 90 or older (indicating high-risk patients)
Nasolacrimal probe in infants (Badgery-Parker et al., 2019)	Any nasolacrimal probe in infants aged <1 year	Probing of nasolacrimal duct in infant in infants aged <1 year	Probing of nasolacrimal duct in infant aged <1 year with diagnosis of inflammation, stenosis, insufficiency, or stricture of lacrimal passages, or other congenital malformation of lacrimal apparatus
Electroconvulsive therapy in children (Badgery-Parker et al., 2019)	Any electroconvulsive therapy in children aged 5-11 years	Any electroconvulsive therapy in children aged 5-11 years	Only children with a diagnosis of depression

^a The narrower definition is set the same as the broader definition.

^b Procedures include surgeries of the breast (K472-K476), colectomy (K719), cholecystectomy (K672), transurethral resection of the prostate (K841), hysterectomy (K872-K879), orthopedic surgeries including arthroscopy (besides hip and knee replacement) (K023-K144), corneal transplant (K259), cataract removal (K282), retinal detachment (K275, K276, K277, K279, K280, K281, K284), hernia repair (K633, K634), and lithotripsy (K768), CABG (K552), aneurysm repair (K560), thromboendarterectomy (K551, K609) PTCA (K546-K549), and pacemaker insertion (K597-K599).

^c Procedures include surgeries included in footnote “a” except for CABG (K552), aneurysm repair (K560), thromboendarterectomy (K551, K609) PTCA (K546-K549), pacemaker insertion (K597-K599)

^d By construction, we evaluated low-value care during the fiscal year 2017 through 2019.

^e Since the reimbursement policy for this service was introduced in the fiscal year 2016, we evaluated low-value care during the fiscal year 2016 through 2019.

Supplementary Table 3. Codes for measures of low-value services

	Codes for identification	Healthcare spending calculation
Antibiotics prescription for the common cold	Anatomical Therapeutic Chemical (ATC) classification system code: J01xx ICD10: J00, J01, J028, J029, J041, J042, J06 (common cold); J12-J18 (pneumonia), J200, J201, J202 (bacterial bronchitis); H66 (otitis media); J36 (peritonsillar abscess); J05 (croup and epiglottitis); J020 (streptococcus pharyngitis); J312 (chronic pharyngitis)	a
Serum T3 level testing for patients with hypothyroidism	Reimbursement code: 160031310, 160033210 (T3 test) ICD10: E02, E03 (hypothyroidism)	a
Pregabalin prescription for back pain	Reimbursement code: 621983701, 621983801, 621983901, 622538201, 622538301, 622538401, 622827701, 622827901, 622834901, 622835001 (pregabalin) ICD10: M430, M431, M4329, M4646, M4649, M471, M4786, M4799, M4800, M4806, M4808, M4809, M510, M511, M512, M513, M518, M519, M5326, M5329, M533, M539, M5416–M5419, M543, M544, M545, M5489, M549, M961, M99, Q762, S33 (back pain); M797 (fibromyalgia); B022, G530 (postherpetic neuralgia); M50, M51 (disc disorder); G50 (trigeminal neuralgia); E10-E14 (diabetes); I70 (arteriosclerosis); T812, G54-G64 (peripheral neuropathy)	a
Spinal injection for low back pain	Reimbursement code: 150235510, 150236010, 150242110, 150266010, 150265010, 150235710, 150350710, 150236010, 150265710, 150351310, 150239110 ICD10: M430, M431, M4329, M4646, M4649, M471, M4786, M4799, M4800, M4806, M4808, M4809, M510, M511, M512, M513, M518, M519, M5326, M5329, M533, M539, M5416–M5419, M543, M544, M545, M5489, M549, M961, M99, Q762, S33 (back pain); M511, M5416-M5419 (radiculopathy)	All outpatient expenses occurring on the same day of service were included in healthcare spending estimates.
Oral betamimetics prescription	Reimbursement code: 610406047, 610461096, 620001965, 620003079, 620006607, 620564904, 620564905, 620564912, 620564913, 620564918, 620564921, 620565301, 620565302, 620006947 (oral betamimetics)	a
Preoperative pulmonary function testing (PFT)	Reimbursement code: 160062610, 160062710, 160062810, 160063010 (PFT); 111000570, 112001110, 112006470, 113016270, 113018570, 111000670, 112001210, 112006570, 113016370, 113018670, 111000770, 112001310, 112006670, 113016470, 113018770 (off-hour visit)	a
Preoperative echocardiogram	Reimbursement code: 160072510, 160072610 (echocardiogram); 111000570, 112001110, 112006470, 113016270, 113018570, 111000670, 112001210, 112006570, 113016370, 113018670, 111000770, 112001310, 112006670, 113016470, 113018770 (off-hour visit)	a
Bone mineral density testing at frequent intervals	Reimbursement code: 160091310, 160186870, 160147310, 160170410 (mineral density test) ICD10: M80, M81, M82 (osteoporosis)	a
Hypercoagulability testing for patients with deep vein thrombosis	Reimbursement code: 160154350, 160164050 (anticardiolipin antibodies), 160169150, 160197610 (lupus anticoagulant), 160192310, 160114110, 160192210, 160124850 (Protein C and S activity and antigen), 160016010 (factor V test) ICD10: I802 (deep vein thrombosis); I269 (pulmonary embolism)	a
Intravenous betamimetics for inhibiting preterm labor, >48h	Reimbursement code: 620002177, 620003459, 620004783, 620006201, 620006329, 620007547, 620569915, 620569916, 620570101, 620570202, 620336901 (betamimetics, intravenous rout)	a
Preoperative stress testing or stress testing for stable coronary disease	Reimbursement code: 160069210, 160069310, 160069410, 160069910, 160070050, 160198810, 170020070, 170027770, 170027870 (stress test); 111000570, 112001110, 112006470, 113016270, 113018570, 111000670, 112001210, 112006570, 113016370, 113018670, 111000770, 112001310, 112006670, 113016470, 113018770 (off-hour visit) ICD10: I20-I25 (ischemic heart disease or angina)	Including healthcare spendings for imaging and reading, and supplies such as contrast media.
Preoperative breast MRI	Reimbursement code: 170035170 (breast MRI); 150121610, 150303110, 150316510, 150262710, 150121710, 150121810, 150121910, 150386510, 150345870, 150345970 (breast cancer surgery); 150121410, 150405810, 150413710 (surgery for benign breast diseases)	Including healthcare spendings for MRI imaging and reading, and supplies such as contrast media.

	ICD10: C50 (breast cancer) (C5001 for breast Paget's disease); R798 (hereditary breast and ovarian cancer syndrome)	
Intravenous sivelestat for acute respiratory disease syndrome	Reimbursement code: 622381901, 622391901, 622393901, 622394601, 622401101, 640462009 (sivelestat)	a
Traction therapy for back pain or neck pain	Reimbursement code: 140048010 (traction therapy)	a
	ICD10: M430, M431, M4329, M4646, M4649, M471, M4786, M4799, M4800, M4806, M4808, M4809, M510, M511, M512, M513, M518, M519, M5326, M5329, M533, M539, M5411, M5416–M5419, M543, M544, M545, M5489, M549, M961, M99, Q762, S33 (back pain); M50, M540, M5411, M542 (neck pain); C412 (malignant spinal tumor); M05, M06, M790 (rheumatoid arthritis); M45, M46 (spondylitis); M80, M81, M82 (osteoporosis)	
Spinal fusion for lumbar stenosis	Reimbursement code: 150314810, 150282510, 150282610, 150314610, 150314710, 150368870, 150368970, 150369070, 150314810, 150369170, 150369370, 150369170, 150397210, 150314210 (spinal fusion) ICD10: M4806 (lumbar stenosis); "M431 (spondylolisthesis); M796 (pain in foot); M511, M5416–M5419 (radiculopathy); M543, M544 (sciatica); Q76 (congenital malformations of spine)	The additional healthcare spending (including the healthcare spending of materials) compared to the healthcare spending of laminectomy was used as an estimate of the healthcare spending.
Endoscopy for dyspepsia for people < 55 years or colonoscopy for constipation in people < 50 years	Reimbursement code: 160093810 (esophagogastroduodenoscopy), 160094710, 160094810, 160094910, 160202750 (colonoscopy) F453, K30, R101 (dyspepsia) K589, K590 (constipation); D50-53, D55-64 (anemia), R131 (dysphagia), R634, R64 (weight loss); C15-26, C784-788 (cancer of digestive system), K20-K31, K35-K38, K40-K44, K50-K52, K55-K64 (except for K589 and K560), K65-K67, K70-K77, K80-K87, K90-K93 (other diseases of the digestive system);	All expenses incurred on the same day of service were included in healthcare spending estimates.
PTH testing for patients with stage 1-3 chronic kidney disease	Reimbursement code: 160035510 (PTH test); 140036710, 140051010, 140051110, 140057810, 140057910, 140058010, 140059310, 140059410, 140060210, 140060310, 140060410, 140059070, 140059170, 140052810, 140058110, 140058210, 140058410, 140058510, 140058610, 140007710, 140008170, 140052570, 140052970, 140007910, 140058770, 140058870, 140033770, 140058970, 140055970, 140029850, 140053670 (dialysis). ICD10: N181, N182, N183 (chronic kidney disease); E8352 (hypercalcemia)	a
Electroencephalography (EEG) for headache	Reimbursement code: 160075310, 160075750, 160075850, 160075950, 160076050, 160200510, 160170610, 160207510, 160187010 (EEG) ICD10: G43, G44 (headache); A080, A081, A084, F445, G253, G40, G41, G433, G513, G934, R56 (epilepsy or convulsions)	a
1, 25-dihydroxyvitamin D testing in the absence of hypercalcemia or decreased kidney function	Reimbursement code: 160158150 ICD10: N181, N182, N183 (CKD); E8352 (hypercalcemia); E211 (secondary hyperparathyroidism); D86 (sarcoidosis); J65, A15-A19, B90 (tuberculosis); C43, C44, C50, C56, C64, C65, C67, C81-C86, C88, C90-C96 (selected neoplasms)	a
Vertebroplasty for osteoporotic vertebral fractures	Reimbursement code: 150355210 (vertebroplasty) ICD10: M8008, M8018, M8028, M8038, M8048, M8058, M8088, M8098, M48.4, M84.4, S12, S220, S221, S320, T08, Y427 (vertebral fracture); C412, C795 (bone cancers); C90 (myeloma); D180 (hemangioma).	All expenses incurred on the same day of service were included in healthcare spending estimates.
Inferior vena cava (IVC) filters for the prevention of pulmonary embolism	Reimbursement code: 150263510 ICD10: I260, I269 (pulmonary embolism); I802 (deep vein thrombosis)	Including the healthcare spending of procedures and supplies
Endotoxin apheresis for sepsis	Reimbursement code: 140037250, 140061610	Including the healthcare spending of procedures and supplies
Artificial liver support for acute liver failure	Reimbursement code: 140008410 ICD10: B150, B162, B171, B172, B190, K711, K720, K729 (acute liver failure); B181, B182, B189, K700, K701, K702, K703, K704, K709, K713, K717, K721, K730, K732, K738, K739, K740, K741, K743, K744, K745, K746, K754, K758, K760, K761 (chronic or subacute liver disease)	Including the healthcare spending of procedures and supplies

Pulmonary artery catheterization (PAC) in the intensive care unit (ICU)	Reimbursement code: 160183910, 160075010, 160075170 (pulmonary artery catheterization); Classification number for reimbursement: A300, A301 (ICU): K00x-K91x (surgical procedures) ICD10: I27 (pulmonary hypertension); I319 (cardiac tamponade)	Including the healthcare spending of procedures and supplies
Arthroscopic surgery for knee osteoarthritis	Reimbursement code: 150309510, 150310410, 150311310, 150312410 ICD10: M150, M153, M159, M17, M1909, M1919, M1929, M1999 (osteoarthritis); M224, M942 (chondromalacia); M232, S832 (meniscal tear)	All expenses incurred on the same day of service were included in healthcare spending estimates.
Renal angioplasty	Reimbursement code: 150152010 ICD10: I150 (renovascular hypertension), I701 (renal atherosclerosis); I773 (fibromuscular dysplasia)	All expenses incurred on the same day of service were included in healthcare spending estimates.
Percutaneous coronary intervention (PCI) with angioplasty or stent placement for stable coronary disease	Reimbursement code: 150375110, 150374910, 150375010, 150375410, 150375210, 150375310 (PCI) (the following codes are used for procedures related to acute coronary syndrome: 150374910, 150375010, 150375210, 150375310); 111000570, 112001110, 112006470, 113016270, 113018570, 111000670, 112001210, 112006570, 113016370, 113018670, 111000770, 112001310, 112006670, 113016470, 113018770 (off-hour visit) ICD10: I20-I25 (ischemic heart disease or angina) (I21-I23 for acute myocardial infarction)	All inpatient expenses occurring on the same day of service were included in healthcare spending estimates.
Intravenous anti-herpes drugs for sudden sensorineural hearing loss	Reimbursement code: 620001341, 620003671, 620003746, 620004633, 620006283, 620006284, 620009268, 621144901, 621384302, 621384303, 621384402, 621384411, 621384414, 621384422, 621384424, 621384425, 621660102, 622325900, 640461002 (intravenous acyclovir) ICD10: H912 (sudden sensorineural hearing loss); A60 (herpes simplex infection), B00-B02 (herpes zoster virus infection); B203 (human immunodeficiency virus diseases in herpes virus infections)	a
Surgery for vesicoureteral reflux	Reimbursement code: 150201950, 150326310, 150365410 ICD10: N137, Q627 (vesicoureteral reflux)	All expenses incurred on the same day of service were included in healthcare spending estimates.
Tricyclic antidepressants prescription for children without other psychological disorders	Reimbursement code: 611170035, 611170036, 611170037, 611170647, 611170785, 611170790, 611170791, 611170796, 611170027, 611170028, 620007173, 620006988, 620155801, 611170143, 611170822, 610463147, 611170283, 611170041, 611170042 (oral tricyclic antidepressants) ICD10: F32, F33 (depression); F01-F31, F34-F99 (other psychological disorders)	a
Carotid endarterectomy in asymptomatic patients	Reimbursement code: 150322710 (carotid endarterectomy); 140036710, 140051010, 140051110, 140057810, 140057910, 140058010, 140059310, 140059410, 140060210, 140060310, 140060410, 140059070, 140059170, 140052810, 140058110, 140058210, 140058410, 140058510, 140058610, 140007710, 140008170, 140052570, 140052970, 140007910, 140058770, 140058870, 140033770, 140058970, 140055970, 140029850, 140053670 (dialysis) ICD10: H340-H342 (retinal artery occlusion); G45 (TIA); I60-I63, I66 (stroke); R25, R430-R432, R270, R278, R279, R290, R291, R295, R683, R414, R471, R478, R20 (nervous and musculoskeletal symptoms); I21-I23 (acute myocardial infarction); (J43, J44 (chronic obstructive pulmonary disease); alcohol related disorder (F10); presence of cardiac pacemaker (Z950)	All expenses incurred on the same day of service were included in healthcare spending estimates.
Nasolacrimal probe in infants	Reimbursement code: 150076710 (nasolacrimal probe) ICD10: H043-H046 (inflammation, stenosis, insufficiency, or stricture of lacrimal passages); Q105 (other congenital malformation of lacrimal apparatus)	All expenses incurred on the same day of service were included in healthcare spending estimates.
Electroconvulsive therapy in children	Reimbursement code: 180019910, 180005010 (electroconvulsive therapy) ICD10: F32, F33 (depression)	All expenses incurred on the same day of service were included in healthcare spending estimates.

ICD10: International Classification of Diseases, Tenth Revision.

^a Including only the healthcare spendings associated with the reimbursement code.

Supplementary Table 4. Change of total number of low-value episodes per 1,000 hospital patients from fiscal year (FY) 2015 to 2019

Definition of low-value care	Total number of low-value episodes /1000 patients ^a		Average annual % change ^b (95% confidence interval)	P value
	FY2015	FY2019		
Narrower definition	120.0	111.5	-2.0 (-3.4 to -0.6)	0.02
Broader definition	205.7	203.7	0.6 (-1.6 to 2.8)	0.45

^a Amongst the 33 identified low-value services, we evaluated the aggregated number of 31 low-value services that were measurable throughout the period, except for bone mineral testing (measurable from FY2017) and breast MRI (measurable from FY2016).


^b Trends (and p values for trend) are determined by calculating average annual percentage change.

Supplementary Table 5. Change of low-value episodes per 1,000 hospital patients from fiscal year (FY) 2015 to 2019 for 17 healthcare services with most episodes involving low-value care (narrower definition) in FY 2019

Services	Narrower definition				Broader definition			
	No of low-value episodes /1000 patients		Average annual % change ^a	P value	No of low-value episodes /1000 patients		Average annual % change ^a	P value
			(95% confidence interval)				(95% confidence interval)	
	FY2015	FY2019			FY2015	FY2019		
Services with decreasing trends								
Antibiotics prescription	37.35	23.61	-11.5 (-13.7 to -9.3)	0.001	45.15	29.41	-10.7 (-12.6 to -8.8)	<0.001
Spinal injection	18.67	14.13	-7.0 (-8.5 to -5.4)	0.001	18.96	14.32	-7.0 (-8.7 to -5.4)	0.001
Oral betamimetics prescription	12.72	9.91	-6.4 (-11.3 to -1.2)	0.03	12.72	9.91	-6.4 (-11.3 to -1.2)	0.03
Intravenous betamimetics	0.90	0.71	-6.0 (-9.6 to -2.3)	0.02	0.90	0.71	-6.0 (-9.6 to -2.3)	0.02
Intravenous sivelestat	0.42	0.19	-16.9 (-28.4 to -3.6)	0.03	0.42	0.19	-16.9 (-28.4 to -3.6)	0.03
Traction therapy	1.05	0.18	-31.6 (-44.0 to -16.4)	0.009	1.68	0.21	-37.3 (-47.6 to -25.1)	0.004
Services with increasing trends								
Serum T3 level testing	21.20	23.33	2.0 (0.6 to 3.4)	0.02	21.20	23.33	2.0 (0.6 to 3.4)	0.02
Pregabalin prescription	12.18	22.90	17.4 (6.3 to 29.7)	0.01	76.08	103.41	8.2 (2.5 to 14.2)	0.02
Echocardiogram	3.53	4.16	4.0 (2.7 to 5.3)	0.002	3.55	4.17	4.0 (2.7 to 5.2)	0.002
Hypercoagulability testing	1.15	1.37	4.9 (2.2 to 7.6)	0.009	1.19	1.47	6.1 (1.7 to 10.6)	0.02
Services with no clear trends								
Pulmonary function testing	8.99	9.51	1.2 (-2.0 to 4.6)	0.31	9.01	9.53	1.2 (-1.9 to 4.5)	0.32
Bone mineral density testing	2.21 ^b	2.95	15.8 (5.7 to 26.7)	0.03	12.59 ^a	14.92	8.9 (-6.0 to 26.0)	0.09
Stress testing	0.58	0.46	-4.9 (-11.6 to 2.4)	0.12	5.63	5.09	-1.9 (-4.5 to 0.8)	0.11
Breast MRI	0.26 ^c	0.28	3.3 (-2.6 to 9.6)	0.14	0.28 ^b	0.30	3.1 (-2.4 to 8.9)	0.14
Spinal fusion	0.13	0.17	5.3 (-6.1 to 18.1)	0.25	0.14	0.19	5.5 (-1.6 to 13.1)	0.09
Endoscopy in adults <55	0.29	0.17	-9.4 (-28.4 to 14.7)	0.28	0.31	0.17	-10.0 (-30.0 to 15.6)	0.27
PTH testing	0.05	0.15	27.7 (0.5 to 62.2)	0.047	0.05	0.17	28.5 (-2.9 to 70.1)	0.07

^a Trends (and p values for trend) are determined by calculating average annual percentage change.^b The estimates for FY2017 were presented because those for FY2015-2016 were unavailable by definition.^c The estimates for FY2016 were presented because those for FY2015 were unavailable by definition.

Supplementary Figure 3. Number of low-value episodes per 1,000 patients seeking care, using the broader definition



T3, Triiodothyronine; MRI, magnetic resonance imaging; PTH, parathyroid hormone.

Supplementary Table 6. Crude probability of receiving at least one of the 33 low-value services in the fiscal year 2019 among adult patients, by patient and hospital characteristics

	No. of patients	No. of patients who received at least one low-value service	Crude probability, % (95% CI)
Patients' age (years)			
18–34	28,840	2,027	7.0
35–49	45,473	2,653	5.8
50–64	61,378	2,948	4.8
65–74	68,363	3,448	5.0
≥ 75	88,221	4,225	4.8
Patients' sex			
Female	157,787	9,237	5.9
Male	134,488	6,064	4.5
Charlson's comorbidity score			
0–1	217,858	10,423	4.8
2–4	63,164	3,842	6.1
≥ 5	11,253	1,036	9.2
Size of the treating hospital			
Small (< 200 beds)	28,987	1,790	6.2
Medium (200–499 beds)	163,280	8,601	5.3
Large (≥ 500 beds)	100,008	4,910	4.9

Supplementary Reference

1. Nishikawa A, Yoshinaga E, Nakamura M, *et al.* Validation study of algorithms to identify malignant tumors and serious infections in a Japanese administrative healthcare database. *Annals of Clinical Epidemiology* 2022;**4**:20–31. doi:[10.37737/ace.22004](https://doi.org/10.37737/ace.22004)